D9319C00001- 1L OC Mono Global RCT

Summary

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or partial response following treatment with standard first-line platinum-based chemotherapy.

Timeline

Start

2021-05-31

Primary completion

2026-07-27

Completion

2027-07-27

Drugs

Indications